Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2022 · 10-Q
Revenue$6.77M$6.77M+4.2% vs Q1 2021 Net Income-$50.52M-$50.52MN/M vs Q1 2021 EPS Diluted-$0.74-$0.74N/M vs Q1 2021 Operating Income-$50,750,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$51,475,000N/M Margins · derivedOperating margin-749.5%+125.7 pt vs Q1 2021
Net margin-746.0%+126.8 pt vs Q1 2021
ended Mar 31, 2022 · filed May 4, 2022 · 34 d after period end